0001209191-21-026294.txt : 20210409
0001209191-21-026294.hdr.sgml : 20210409
20210409175505
ACCESSION NUMBER: 0001209191-21-026294
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210407
FILED AS OF DATE: 20210409
DATE AS OF CHANGE: 20210409
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Scherle Peggy
CENTRAL INDEX KEY: 0001824632
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39527
FILM NUMBER: 21818746
MAIL ADDRESS:
STREET 1: C/O PRELUDE THERAPEUTICS INCORPORATED
STREET 2: 200 POWDER MILL ROAD
CITY: WILMINGTON
STATE: DE
ZIP: 19803
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Prelude Therapeutics Inc
CENTRAL INDEX KEY: 0001678660
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 811384762
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0331
BUSINESS ADDRESS:
STREET 1: 200 POWDER MILL ROAD
CITY: WILMINGTON
STATE: DE
ZIP: 19803
BUSINESS PHONE: (302) 547-3768
MAIL ADDRESS:
STREET 1: 200 POWDER MILL ROAD
CITY: WILMINGTON
STATE: DE
ZIP: 19803
FORMER COMPANY:
FORMER CONFORMED NAME: Prelude Therapeutics Inc.
DATE OF NAME CHANGE: 20160630
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-04-07
0
0001678660
Prelude Therapeutics Inc
PRLD
0001824632
Scherle Peggy
C/O PRELUDE THERAPEUTICS INCORPORATED
200 POWDER MILL ROAD
WILMINGTON
DE
19803
0
1
0
0
Chief Scientific Officer
Common Stock
2021-04-07
4
A
0
15370
1.43
A
188290
D
Common Stock
2021-04-07
4
S
0
8289
39.0162
D
180001
D
Common Stock
2021-04-07
4
S
0
6881
39.6278
D
173120
D
Common Stock
2021-04-07
4
S
0
200
40.30
D
172920
D
Employee Stock Option (right to buy)
1.43
2021-04-07
4
M
0
15370
0.00
D
2028-11-12
Common Stock
15370
71090
D
Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met.
The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.26 to $39.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.26 to $40.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
The stock option vested as to 25% of the total shares monthly beginning on November 13, 2019, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date.
/s/ Brian Piper, Attorney-in-Fact
2021-04-09